{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:51:38Z","timestamp":1790949098240,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Artemisinin-based combinations therapy (ACT) is the current frontline curative therapy for uncomplicated malaria in Burkina Faso. Sulfadoxine-pyrimethamine (SP) is used for the preventive treatment of pregnant women (IPTp), while SP plus amodiaquine (SP-AQ) is recommended for children under five in seasonal malaria chemoprevention (SMC). This study aimed to assess the proportions of mutations in the\n                      <jats:italic>P. falciparum multidrug-resistance 1<\/jats:italic>\n                      (\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      ),\n                      <jats:italic>P. falciparum chloroquine resistance transporter (Pfcrt), P. falciparum dihydrofolate reductase (pfdhfr)<\/jats:italic>\n                      , and\n                      <jats:italic>P. falciparum dihydropteroate synthase (pfdhps)<\/jats:italic>\n                      , genes from isolates collected during household surveys in Burkina Faso.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Dried blood spots from\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      -positive cases at three sites (Orodara, Gaoua, and Banfora) collected during the peak of transmission were analysed for mutations in\n                      <jats:italic>Pfcrt<\/jats:italic>\n                      (codons 72\u201376, 93, 97, 145, 218, 343, 350 and 353),\n                      <jats:italic>Pfmdr-1<\/jats:italic>\n                      (codons 86, 184, 1034, 1042 and 1246)\n                      <jats:italic>dhfr<\/jats:italic>\n                      (codons 51, 59, 108, 164) and\n                      <jats:italic>dhps<\/jats:italic>\n                      (at codons 431, 436, 437, 540, 581, 613) genes using deep sequencing of multiplexed Polymerase chaine reaction (PCR) amplicons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 377 samples analysed, 346 (91.7%), 369 (97.9%), 368 (97.6%), and 374 (99.2%) were successfully sequenced for\n                      <jats:italic>Pfcrt, Pfmdr-1, dhfr<\/jats:italic>\n                      , and\n                      <jats:italic>dhps<\/jats:italic>\n                      , respectively. Most of the samples had a\n                      <jats:italic>Pfcrt<\/jats:italic>\n                      wild-type allele (89.3%). The 76T mutation was below 10%. The most frequent\n                      <jats:italic>Pfmdr-1<\/jats:italic>\n                      mutation was detected at codon 184 (Y\u2009&gt;\u2009F, 30.9%). The single mutant genotype (N\n                      <jats:bold>F<\/jats:bold>\n                      SND) predominated (66.7%), followed by the wild-type genotype (NYSND, 30.4%). The highest\n                      <jats:italic>dhfr<\/jats:italic>\n                      mutations were observed at codon 59R (69.8%), followed by codons 51I (66.6%) and 108\u00a0N (14.7%). The double mutant genotype (AC\n                      <jats:bold>IR<\/jats:bold>\n                      SI) predominated (52.4%). For mutation in the\n                      <jats:italic>dhps<\/jats:italic>\n                      gene, the highest frequency was observed at codon 437\u00a0K (89.3%), followed by codons 436\u00a0A (61.2%), and 613\u00a0S (14.4%). The double mutant genotype (I\n                      <jats:bold>AK<\/jats:bold>\n                      KAA) and the single mutant genotype (IS\n                      <jats:bold>K<\/jats:bold>\n                      KAA) were predominant (37.7% and 37.2%, respectively). The most frequent\n                      <jats:italic>dhfr\/dhps<\/jats:italic>\n                      haplotypes were the triple mutant AC\n                      <jats:bold>IR<\/jats:bold>\n                      SI\/I\n                      <jats:bold>A<\/jats:bold>\n                      KKAA (23%), the wild-type ACNCSI\/ISKKAA (19%) and the double mutant AC\n                      <jats:bold>IR<\/jats:bold>\n                      SI\/ISKKAA (14%). A septuple mutant AC\n                      <jats:bold>IRN<\/jats:bold>\n                      I\/\n                      <jats:bold>VAK<\/jats:bold>\n                      K\n                      <jats:bold>G<\/jats:bold>\n                      A was observed in 2 isolates from Gaoua (0.5%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The efficacy of ACT partner drugs and drugs used in IPTp and SMC does not appear to be affected by the low proportion of highly resistant mutants observed in this study. Continued monitoring, including molecular surveillance, is critical for decision-making on effective treatment policy in Burkina Faso.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-023-04645-9","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T11:05:29Z","timestamp":1689851129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Plasmodium falciparum drug resistance-associated mutations in isolates from children living in endemic areas of Burkina Faso"],"prefix":"10.1186","volume":"22","author":[{"given":"Casimire Wendlamita","family":"Tarama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harouna","family":"Sor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafama","family":"Siribi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siaka","family":"D\u00e9b\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9n\u00e9","family":"Kinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adama","family":"Ganou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendyam G\u00e9rard","family":"Nonkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida","family":"Tiendrebeogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Bantango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassoum","family":"Yira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aladari","family":"Sagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Ilboudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Y\u00e9ri","family":"Hien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa Wandaogo","family":"Guelb\u00e9ogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NFale","family":"Sagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Traor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adama","family":"Gansan\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"4645_CR1","unstructured":"WHO. World malaria report 2022. Geneva, World Health Organization. 2022."},{"key":"4645_CR2","volume-title":"De Hygi\u00e8ne Pubique du Burkina Faso. Annuaire Statistique 2021","author":"Minist\u00e8re de la Sant\u00e9 et","year":"2021","unstructured":"Minist\u00e8re de la Sant\u00e9 et. De Hygi\u00e8ne Pubique du Burkina Faso. Annuaire Statistique 2021. Burkina Faso: Ouagadougou; 2021."},{"issue":"Suppl 3","key":"4645_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2875-9-S3-S2","volume":"9","author":"B Greenwood","year":"2010","unstructured":"Greenwood B. Anti-malarial drugs and the prevention of malaria in the population of malaria endemic areas. Malar J. 2010;9(Suppl 3):2.","journal-title":"Malar J"},{"key":"4645_CR4","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nrmicro2239","volume":"7","author":"RT Eastman","year":"2009","unstructured":"Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009;7:864\u201374.","journal-title":"Nat Rev Microbiol"},{"key":"4645_CR5","unstructured":"Programme National de Lutte contre le Paludisme. Directives nationales pour la prise en charge du paludisme dans les formations sanitaires du Burkina Faso. Ouagadougou, Burkina Faso, 2021."},{"key":"4645_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1051\/parasite\/2016069","volume":"23","author":"AF Som\u00e9","year":"2016","unstructured":"Som\u00e9 AF, Sorgho H, Zongo I, Bazi\u00e9 T, Niki\u00e9ma F, Sawadogo A, et al. Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso. Parasite. 2016;23:60.","journal-title":"Parasite"},{"key":"4645_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.11604\/pamj.2015.21.101.6437","volume":"21","author":"P Sondo","year":"2015","unstructured":"Sondo P, Derra K, Tarnagda Z, Nakanabo SD, Zampa O, Kazienga A, et al. Dynamic of Plasmodium falciparum chloroquine resistance transporter gene pfcrt K76T mutation five years after withdrawal of chloroquine in Burkina Faso. Pan Afr Med J. 2015;21:101.","journal-title":"Pan Afr Med J"},{"key":"4645_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12936-021-04026-0","volume":"21","author":"A Gansan\u00e9","year":"2022","unstructured":"Gansan\u00e9 A, Candrinho B, Mbituyumuremyi A, Uhomoibhi P, NFal\u00e9 S, Mohammed AB, et al. Design and methods for a quasi-experimental pilot study to evaluate the impact of dual active ingredient insecticide-treated nets on malaria burden in five regions in sub-saharan Africa. Malar J. 2022;21:19.","journal-title":"Malar J"},{"key":"4645_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"4645_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijpddr.2021.06.001","volume":"16","author":"L Ndwiga","year":"2021","unstructured":"Ndwiga L, Kimenyi KM, Wamae K, Osoti V, Akinyi M, Omedo I, et al. A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa. Int J Parasitol Drugs Drug Resist. 2021;16:155\u201361.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"4645_CR11","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JLM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"4645_CR12","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1128\/AAC.00835-15","volume":"59","author":"R Leang","year":"2015","unstructured":"Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719\u201326.","journal-title":"Antimicrob Agents Chemother"},{"key":"4645_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1128\/AAC.00686-12","volume":"57","author":"R Leang","year":"2013","unstructured":"Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother. 2013;57:818\u201326.","journal-title":"Antimicrob Agents Chemother."},{"key":"4645_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","volume":"16","author":"C Amaratunga","year":"2016","unstructured":"Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin\u2013piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16:357\u201365.","journal-title":"Lancet Infect Dis"},{"key":"4645_CR15","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1473-3099(12)70181-0","volume":"12","author":"C Amaratunga","year":"2012","unstructured":"Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012;12:851\u20138.","journal-title":"Lancet Infect Dis"},{"key":"4645_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.trstmh.2008.11.002","volume":"103","author":"CV Plowe","year":"2009","unstructured":"Plowe CV. The evolution of drug-resistant malaria. Trans R Soc Trop Med Hyg. 2009;103:11\u20134.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"4645_CR17","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S1097-2765(05)00077-8","volume":"6","author":"DA Fidock","year":"2000","unstructured":"Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6:861\u201371.","journal-title":"Mol Cell"},{"key":"4645_CR18","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.1128\/AAC.03494-14","volume":"58","author":"N Wurtz","year":"2014","unstructured":"Wurtz N, Fall B, Pascual A, Fall M, Baret E, Camara C, et al. Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin. Antimicrob Agents Chemother. 2014;58:7032\u201340.","journal-title":"Antimicrob Agents Chemother"},{"key":"4645_CR19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1365-2958.2005.04729.x","volume":"57","author":"ABS Sidhu","year":"2005","unstructured":"Sidhu ABS, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol. 2005;57:913\u201326.","journal-title":"Mol Microbiol"},{"key":"4645_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1365-2958.2007.05664.x","volume":"64","author":"CP Sanchez","year":"2007","unstructured":"Sanchez CP, Rohrbach P, McLean JE, Fidock DA, Stein WD, Lanzer M. Differences in trans-stimulated chloroquine efflux kinetics are linked to PfCRT in Plasmodium falciparum. Mol Microbiol. 2007;64:407\u201320.","journal-title":"Mol Microbiol"},{"key":"4645_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJM200101253440403","volume":"344","author":"A Djimd\u00e9","year":"2001","unstructured":"Djimd\u00e9 A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourt\u00e9 Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001;344:257\u201363.","journal-title":"N Engl J Med"},{"key":"4645_CR22","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1128\/AAC.47.8.2418-2423.2003","volume":"47","author":"AL Pickard","year":"2003","unstructured":"Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother. 2003;47:2418\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"4645_CR23","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1038\/s41467-018-05652-0","volume":"9","author":"LS Ross","year":"2018","unstructured":"Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, K\u00fcmpornsin K, et al. Emerging southeast asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat Commun. 2018;9:3314.","journal-title":"Nat Commun"},{"key":"4645_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.actatropica.2005.04.008","volume":"94","author":"MT Duraisingh","year":"2005","unstructured":"Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop. 2005;94:181\u201390.","journal-title":"Acta Trop"},{"key":"4645_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1124\/pr.57.1.4","volume":"57","author":"A Gregson","year":"2005","unstructured":"Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev. 2005;57:117\u201345.","journal-title":"Pharmacol Rev"},{"key":"4645_CR26","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S1471-4922(01)02085-2","volume":"17","author":"CH Sibley","year":"2001","unstructured":"Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 2001;17:582\u20138.","journal-title":"Trends Parasitol"},{"key":"4645_CR27","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1017\/S0031182011000746","volume":"138","author":"I Naidoo","year":"2011","unstructured":"Naidoo I, Roper C. Drug resistance maps to guide intermittent preventive treatment of malaria in african infants. Parasitology. 2011;138:1469\u201379.","journal-title":"Parasitology"},{"key":"4645_CR28","doi-asserted-by":"publisher","first-page":"e0236920","DOI":"10.1371\/journal.pone.0236920","volume":"15","author":"DD Soma","year":"2020","unstructured":"Soma DD, Zogo BM, Som\u00e9 A, Tchiekoi BN, Hien DF, de Pooda S. Anopheles bionomics, insecticide resistance and malaria transmission in southwest Burkina Faso: a pre-intervention study. PLoS ONE. 2020;15:e0236920.","journal-title":"PLoS ONE"},{"key":"4645_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12936-019-2747-5","volume":"18","author":"PS Epopa","year":"2019","unstructured":"Epopa PS, Collins CM, North A, Millogo AA, Benedict MQ, Tripet F, et al. Seasonal malaria vector and transmission dynamics in western Burkina Faso. Malar J. 2019;18:113.","journal-title":"Malar J"},{"key":"4645_CR30","unstructured":"Cinqui\u00e8me. Recensement G\u00e9n\u00e9ral de la Population et de l\u2019Habitation du Burkina Faso, 2022."},{"key":"4645_CR31","volume-title":"Epidemiology, evidence-based medicine and public health","author":"Y Ben-Shlomo","year":"2013","unstructured":"Ben-Shlomo Y, Brookes S, Hickman M. Epidemiology, evidence-based medicine and public health. 6th ed. New Jersey: Wiley-Blackwell; 2013.","edition":"6"},{"key":"4645_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12936-019-2817-8","volume":"18","author":"K Zainabadi","year":"2019","unstructured":"Zainabadi K, Nyunt MM, Plowe CV. An improved nucleic acid extraction method from dried blood spots for amplification of Plasmodium falciparum kelch13 for detection of artemisinin resistance. Malar J. 2019;18:192.","journal-title":"Malar J"},{"key":"4645_CR33","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8082","volume":"8","author":"M Maraka","year":"2020","unstructured":"Maraka M, Akala HM, Amolo AS, Juma D, Omariba D, Cheruiyot A, et al. A seven-year surveillance of epidemiology of malaria reveals travel and gender are the key drivers of dispersion of drug resistant genotypes in Kenya. PeerJ. 2020;8: e8082.","journal-title":"PeerJ"},{"key":"4645_CR34","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1086\/375419","volume":"187","author":"JG Kublin","year":"2003","unstructured":"Kublin JG, Cortese JF, Njunju EM, Mukadam G, Wirima RA, Kazembe JJ. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003;187:1870\u20135.","journal-title":"J Infect Dis"},{"key":"4645_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12936-015-0850-9","volume":"14","author":"WC Kiarie","year":"2015","unstructured":"Kiarie WC, Wangai L, Agola E, Kimani FT, Hungu C. Chloroquine sensitivity: diminished prevalence of chloroquine-resistant gene marker pfcrt-76 13 years after cessation of chloroquine use in Msambweni, Kenya. Malar J. 2015;14:328.","journal-title":"Malar J"},{"key":"4645_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12936-020-03281-x","volume":"19","author":"FT Foguim","year":"2020","unstructured":"Foguim FT, Bogreau H, Gendrot M, Mosnier J, Fonta I, Benoit N, et al. Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against african Plasmodium falciparum isolates. Malar J. 2020;19:201.","journal-title":"Malar J"},{"key":"4645_CR37","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1590\/0074-0276130274","volume":"108","author":"G Awasthi","year":"2013","unstructured":"Awasthi G, Das A. Genetics of chloroquine-resistant malaria: a haplotypic view. Mem Inst Oswaldo Cruz. 2013;108:947\u201361.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"4645_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/1475-2875-9-174","volume":"9","author":"BE Gama","year":"2010","unstructured":"Gama BE, Pereira-Carvalho GAL, Lutucuta Kosi FJI, Almeida de Oliveira NK, Fortes F, Rosenthal PJ, et al. Plasmodium falciparum isolates from Angola show the StctVMNT haplotype in the pfcrt gene. Malar J. 2010;9:174.","journal-title":"Malar J"},{"key":"4645_CR39","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1086\/504269","volume":"193","author":"M Alifrangis","year":"2006","unstructured":"Alifrangis M, Dalgaard MB, Lusingu JP, Vestergaard LS, Staalsoe T, Jensen ATR, et al. Occurrence of the southeast Asian\/South american SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. J Infect Dis. 2006;193:1738\u201341.","journal-title":"J Infect Dis"},{"key":"4645_CR40","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4269\/ajtmh.14-0031","volume":"91","author":"M Venkatesan","year":"2014","unstructured":"Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833\u201343.","journal-title":"Am J Trop Med Hyg"},{"key":"4645_CR41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s12936-019-2947-z","volume":"18","author":"AO Idowu","year":"2019","unstructured":"Idowu AO, Oyibo WA, Bhattacharyya S, Khubbar M, Mendie UE, Bumah VV, et al. Rare mutations in Pfmdr1 gene of Plasmodium falciparum detected in clinical isolates from patients treated with anti-malarial drug in Nigeria. Malar J. 2019;18:319.","journal-title":"Malar J"},{"key":"4645_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-264","volume":"13","author":"RA Kavishe","year":"2014","unstructured":"Kavishe RA, Paulo P, Kaaya RD, Kalinga A, van Zwetselaar M, Chilongola J, et al. Surveillance of artemether-lumefantrine associated Plasmodium falciparum multidrug resistance protein-1 gene polymorphisms in Tanzania. Malar J. 2014;13: 264.","journal-title":"Malar J"},{"key":"4645_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.molbiopara.2007.09.008","volume":"157","author":"JK Lekostaj","year":"2008","unstructured":"Lekostaj JK, Amoah LE, Roepe PD. A single S1034C mutation confers altered drug sensitivity to PfMDR1 ATPase activity that is characteristic of the 7G8 isoform. Mol Biochem Parasitol. 2008;157:107\u201311.","journal-title":"Mol Biochem Parasitol"},{"key":"4645_CR44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/tropicalmed7080155","volume":"7","author":"I Issa","year":"2022","unstructured":"Issa I, Lamine MM, Hubert V, Ilagouma A, Adehossi E, Mahamadou A, et al. Prevalence of mutations in the Pfdhfr, Pfdhps, and Pfmdr1 genes of malarial parasites isolated from symptomatic patients in Dogondoutchi, Niger. Trop Med Infect Dis. 2022;7:155.","journal-title":"Trop Med Infect Dis"},{"key":"4645_CR45","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/tmi.12305","volume":"19","author":"C Geiger","year":"2014","unstructured":"Geiger C, Compaore G, Coulibaly B, Sie A, Dittmer M, Sanchez C, et al. Substantial increase in mutations in the genes pfdhfr and pfdhps puts sulphadoxine\u2013pyrimethamine-based intermittent preventive treatment for malaria at risk in Burkina Faso. Trop Med Int Health. 2014;19:690\u20137.","journal-title":"Trop Med Int Health"},{"key":"4645_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12936-019-2734-x","volume":"18","author":"T Jiang","year":"2019","unstructured":"Jiang T, Chen J, Fu H, Wu K, Yao Y, Eyi JUM, et al. High prevalence of pfdhfr\u2013pfdhps quadruple mutations associated with sulfadoxine\u2013pyrimethamine resistance in Plasmodium falciparum isolates from Bioko Island, Equatorial Guinea. Malar J. 2019;18:101.","journal-title":"Malar J"},{"key":"4645_CR47","doi-asserted-by":"crossref","unstructured":"Dosoo DK, Bailey JA, Asante KP, Oppong FB, Niar\u00e9 K, Opoku-Mensah J et al. The prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine among pregnant women at first antenatal clinic attendance and delivery in the forest-savannah area of Ghana. PLoS ONE 17:e0271489.","DOI":"10.1371\/journal.pone.0271489"},{"key":"4645_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/fmaa120","volume":"67","author":"LL Afutu","year":"2021","unstructured":"Afutu LL, Boampong JN, Quashie NB. High prevalence of molecular markers of Plasmodium falciparum resistance to sulphadoxine-pyrimethamine in parts of Ghana: a threat to ITPTp-SP? J Trop Pediatr. 2021;67: fmaa120.","journal-title":"J Trop Pediatr"},{"key":"4645_CR49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ijpddr.2016.08.004","volume":"6","author":"MC Oguike","year":"2016","unstructured":"Oguike MC, Falade CO, Shu E, Enato IG, Watila I, Baba ES, et al. Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V. Int J Parasitol Drugs Drug Resist. 2016;6:220\u20139.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"4645_CR50","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.4269\/ajtmh.18-0009","volume":"98","author":"J Osarfo","year":"2018","unstructured":"Osarfo J, Tagbor H, Magnussen P, Alifrangis M. Molecular markers of Plasmodium falciparum drug resistance in parasitemic pregnant women in the middle forest belt of Ghana. Am J Trop Med Hyg. 2018;98:1714\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"4645_CR51","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1093\/jac\/dkv160","volume":"70","author":"P Chauvin","year":"2015","unstructured":"Chauvin P, Menard S, Iriart X, Nsango SE, Tchioffo MT, Abate L, et al. Prevalence of Plasmodium falciparum parasites resistant to sulfadoxine\/pyrimethamine in pregnant women in Yaound\u00e9, Cameroon: emergence of highly resistant pfdhfr\/pfdhps alleles. J Antimicrob Chemother. 2015;70:2566\u201371.","journal-title":"J Antimicrob Chemother"},{"key":"4645_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-8-89","volume":"8","author":"S Picot","year":"2009","unstructured":"Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J. 2009;8: 89.","journal-title":"Malar J"},{"key":"4645_CR53","unstructured":"Peters W. Chemotherapy and drug resistance in malaria, vol. 2, 2nd edn. London: Academic Press; 1987. ISBN 0 12 552721 7 (Vol. 1), 0 12 552722 5 (Vol. 2)."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04645-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-023-04645-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04645-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T11:06:57Z","timestamp":1689851217000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-023-04645-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4645"],"URL":"https:\/\/doi.org\/10.1186\/s12936-023-04645-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2724516\/v1","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"22 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved and received authorization no. 2022-05-117 from the Burkina Faso Health Research Ethics Committee. The parents or guardians of the minor participants gave their written informed consent before being recruited for the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}